Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Chronic SUNHA
NCT04905121Phase 1Terminated
- Sponsor
- Beckley Psytech
- Start
- Aug 2021
- Primary completion
- Apr 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in short-lasting unilateral neuralgiform headache attacks (SUNHA), sponsored by Beckley Psytech. Primary endpoints: Percentage of patients with treatment emergent adverse events at 39 days, Paired Associates Learning scores at 11 days and 6 more. Started Aug 2021; status: terminated.
02
Drugs
psilocybin
03
Conditions
short-lasting unilateral neuralgiform headache attacks (SUNHA)
Beyond the preview
Go deeper on NCT04905121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04905121.